- Home
- NXTC vs SINT Comparison
NXTC vs SINT Comparison
Compare NXTC & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- SINT
- Stock Information
- Founded
- NXTC 2015
- SINT 1996
- Country
- NXTC United States
- SINT United States
- Employees
- NXTC N/A
- SINT N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- SINT Medical/Dental Instruments
- Sector
- NXTC Health Care
- SINT Health Care
- Exchange
- NXTC Nasdaq
- SINT Nasdaq
- Market Cap
- NXTC 13.0M
- SINT 11.6M
- IPO Year
- NXTC 2019
- SINT 2014
- Fundamental
- Price
- NXTC $10.77
- SINT $3.36
- Analyst Decision
- NXTC Strong Buy
- SINT Strong Buy
- Analyst Count
- NXTC 2
- SINT 1
- Target Price
- NXTC $25.50
- SINT $25.00
- AVG Volume (30 Days)
- NXTC 49.2K
- SINT 104.8K
- Earning Date
- NXTC 11-06-2025
- SINT 11-11-2025
- Dividend Yield
- NXTC N/A
- SINT N/A
- EPS Growth
- NXTC N/A
- SINT N/A
- EPS
- NXTC N/A
- SINT N/A
- Revenue
- NXTC N/A
- SINT $1,861,000.00
- Revenue This Year
- NXTC N/A
- SINT N/A
- Revenue Next Year
- NXTC N/A
- SINT $80.00
- P/E Ratio
- NXTC N/A
- SINT N/A
- Revenue Growth
- NXTC N/A
- SINT N/A
- 52 Week Low
- NXTC $2.69
- SINT $1.71
- 52 Week High
- NXTC $19.20
- SINT $8.60
- Technical
- Relative Strength Index (RSI)
- NXTC 77.64
- SINT 37.76
- Support Level
- NXTC $6.23
- SINT $3.91
- Resistance Level
- NXTC $13.17
- SINT $4.50
- Average True Range (ATR)
- NXTC 0.91
- SINT 0.37
- MACD
- NXTC 0.50
- SINT -0.10
- Stochastic Oscillator
- NXTC 67.51
- SINT 7.97
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About SINT SiNtx Technologies Inc.
SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.